Late-onset neutropenia following rituximab treatment for rheumatologic conditions

Clinical Rheumatology

Volumn 33, Issue 9, 2014, Pages 1337-1340

  Breuer, Gabriel S ^a   Ehrenfeld, Michael ^b   Rosner, Itzhak ^c,d   Balbir Gurman, Alexandra ^e   Zisman, Devy ^f   Oren, Shirley ^g   Paran, Daphna ^h  

^a HEBREW UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c BNAI ZION MEDICAL CENTER   (Israel)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^e Rambam Health Care Campus ^*  (Israel)

^f CARMEL MEDICAL CENTER   (Israel)

^g RABIN MEDICAL CENTER   (Israel)

^h TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Autoimmune disease; Neutropenia; Rituximab

Indexed keywords

AZATHIOPRINE; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DICLOFENAC; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; TAZOBACTAM; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

AGED; ARTICLE; AUTOIMMUNE DISEASE; BLAST CELL; BLOOD CELL COUNT; BONE MARROW BIOPSY; CELL CYCLE ARREST; CLINICAL ARTICLE; FEMALE; HUMAN; INFORMATION RETRIEVAL; ISRAEL; LATE ONSET NEUTROPENIA; LEUKOCYTE COUNT; MIXED CONNECTIVE TISSUE DISEASE; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT CONTRAINDICATION; VERY ELDERLY; ADULT; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; MIXED CONNECTIVE TISSUE DISEASE; NEUTROPENIA; YOUNG ADULT;

EID: 84906791943     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-014-2562-x     Document Type: Article

References (13)

1. Coiffier B (2007) Rituximab therapy in malignant lymphoma. Oncogene 26:3603-3613
2. Edwards JCW, Szczepaniski L, Szechinski J et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 357:2572-2580
3. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC (2006) Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 54:613-620 (Pubitemid 43228639)
4. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, RAVE-ITN Research Group (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363(3):221-232
5. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363(3):211-220
6. Berentsen S (2007) Rituximab for the treatment of autoimmune cytopenias. Haematologica 92:1589-1596
7. Carr DR, Heffernan MP (2007) Off-label uses of rituximab in dermatology. Dermatol Ther 20:277-287 (Pubitemid 350029316)
8. Dörner T, Radbruch A, Burmester GR (2009) B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol 5(8):433-441
9. Lemieux B, Tartas S, Traulle C et al (2004) Rituximab-related lateonset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 33:921-923 (Pubitemid 38660125)
10. Wolach O, Bairey O, Lahaw M (2010) Late-onset neutropenia after rituximab treatment. Case series and comprehensive review of the literature. Medicine 89:308-318
11. Besada E, Koldingsnes W, Nossent J (2012) Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: a case review analysis from a single center. QJM 105(6):545-550
12. Tesfa D, Ajeganova S, Hägglund H, Sander B, Fadeel B, Hafström I, Palmblad J (2011) Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum 63(8):2209-2214
13. Hincks I, Woodcock BE, Thachil J (2011) Is rituximab-induced lateonset neutropenia a good prognostic indicator in lymphoproliferative disorders? Br J Haematol 153:411-413